Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR000025)
Formula
SVG example
Hydration
Reactant Acalabrutinib Product ACP-5134
Reactant Info Product Info
Metabolic Type Other reaction - Hydration
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR000024 Acalabrutinib Acalabrutinib M2 metabolite Oxidation - Amide Hydrolysis; Oxidation Acalabrutinib [1]
MR000026 Acalabrutinib Acalabrutinib M25 metabolite Oxidation - Dehydration; Oxidation Acalabrutinib [1]
MR000027 Acalabrutinib Acalabrutinib M37 metabolite Oxidation - N-Dealkylation Acalabrutinib [1]
MR000022 Acalabrutinib ACP-5530 Conjugation - Glutathione Conjugation Acalabrutinib [1]
MR000028 Acalabrutinib ACP-5825 Oxidation - Hydroxylation Acalabrutinib [1]
MR000023 Acalabrutinib ACP-5862 Oxidation - Oxidation Acalabrutinib [1], [2], [3]
Other MR(s) Related to The Product of This MR
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR000020 ACP-5134 Acalabrutinib M24 metabolite Reduction - Reduction Acalabrutinib [1]
MR000021 ACP-5134 Acalabrutinib M45 metabolite Reduction - Reduction Acalabrutinib [1]
References
1 Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans Drug Metab Dispos. 2019 Feb;47(2):145-154. doi: 10.1124/dmd.118.084459.
2 Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors?. J Pharmacol Exp Ther. 2023 Jan;384(1):173-186. doi: 10.1124/jpet.122.001116.
3 Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1294-1307. doi: 10.1002/cpdd.1153.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.